The abstract is read at the publisher; the summary is JClub's.
Genome-wide association studies have transformed understanding of stroke’s genetic architecture, while monogenic cerebral small vessel disease and polygenic risk scores are increasingly shaping clinical genetics workflows.
- Why it matters: Clinicians need practical guidance on whether and how stroke genomics should affect testing, risk prediction, prevention, and emerging therapeutic decisions.
- What they did: This review summarizes recent stroke genetics advances, focusing on genetic architecture, when to test for monogenic cerebral small vessel disease, and how polygenic risk scores and genomics-informed therapeutics are being considered.
- The result: The synthesis links current evidence to four clinician-facing questions, outlining how genetic testing strategies, risk stratification, and therapeutic implications may evolve from genomic discoveries.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.